Risk of post-transplant cyclophosphamide-related cardiotoxicity in allogeneic stem cell transplantation

Clicks: 1
ID: 323392
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #223 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Although post-transplant cyclophosphamide (PT-Cy) is currently widely used to prevent graft-versus-host disease (GvHD) following allogeneic hematopoietic stem cell transplantation (alloHSCT), concerns remain regarding its cardiotoxicity. Purpose The aim was to investigate the association between early cardiotoxicity occurring within the first 100 days post-transplant and PT-Cy. Methods We conducted a monocentric retrospective observational study including all consecutive patients who underwent alloHSCT at our Hospital between July 2011 and July 2023. The primary endpoint was a composite of early cardiotoxicity, including cardiovascular death, heart failure (HF), myocarditis, pericardial disease, electrical disorders, and acute arterial events. A propensity-score matching was performed to balance characteristics between patients who received post-transplant PT-Cy and those who did not. Predictors of early cardiotoxicity were analyzed using Fine-and-Gray subdistribution hazard models. Results Among 1,381 patients, 143 (10%) experienced early cardiotoxicity within 100 days post-transplant. The most frequent events were HF (53%), electrical disorders (20%), and pericardial disease (19%). Age (sHR 1.01; 95% CI: 1.00-1.03; p=0.028), prior HF (sHR 2.02; 95% CI: 1.04-3.93; p=0.037), prior cancer therapy–related cardiac dysfunction (sHR 4.24; 95% CI: 2.05-8.78; p<0.001), hypertension (sHR 1.54; 95% CI: 1.00-2.36; p=0.047), and PT-Cy (sHR 1.62; 95% CI: 1.07-2.44; p=0.022) were independently associated with early cardiotoxicity. After 1:1 propensity score–matching, the administration of PT-Cy remained associated with cardiotoxicity (HR=2.00; 95% CI: 1.05-3.80; p=0.035). Conclusions The administration of PT-Cy was independently associated with an increased risk of early cardiotoxicity, particularly HF. These results underscore the need for early cardiovascular risk assessment and tailored surveillance, particularly in patients receiving PT-Cy.Early cardiotoxicity Hematologic outcomes
Reference Key
openalex_W7172264116 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors T Goncalves, R Hadjali, F Chevillon, B Sibilia, T Pezel, S Toupin, N Dhedin, M Jestin, F Sicre De Fontbrune, A Xhaard, R Peffault De Latour, A Cohen Solal, J G Dillinger, P Henry, M Robin
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.044
URL
https://doi.org/10.1093/eurheartjsupp/suag097.044
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.